Experimental combo for advanced tumors falls short in early trial
NCT ID NCT05571969
First seen Jun 11, 2026 · Last updated Jun 11, 2026
Summary
This early-phase study tested a new drug called 2X-121, alone and combined with another drug (dovitinib), in 14 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find safe doses and check for side effects. The study was terminated early, so no clear conclusions about effectiveness could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology
Huntersville, North Carolina, 28078, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.